Bausch Health Companies Inc. (BHC)

Market Cap	1.84B -19.2%
Revenue (ttm)	10.53B +8.2%
Net Income	-1.21B
EPS	-3.25
Shares Out	373.48M
PE Ratio	n/a
Forward PE	1.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	814,960
Open	4.870
Previous Close	4.810
Day's Range	4.850 - 5.010
52-Week Range	4.565 - 8.685
Beta	0.42
Analysts	Hold
Price Target	7.40 (+49.8%)
Earnings Date	Jul 29, 2026

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,300
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Analyst Summary

According to 7 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $7.4, which is an increase of 49.80% from the latest price.

Price Target

$7.4

(49.80% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 7, 2026

Data Sources Report a data error